Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508602 | 0.79 | MEN1 (0.75) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL14819072 | 0.79 | MEN1 (0.75) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL14819071 | 0.67 | TAS1R3 (0.50) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL15020438 | 0.67 | TAS1R3 (0.50) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL28340851 | 0.66 | POLB (0.57) | MAPTMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL14782069 | 0.65 | MEN1 (0.84) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL14819076 | 0.65 | MEN1 (0.78) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL22879014 | 0.65 | MEN1 (0.62) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL15020617 | 0.65 | TAS1R3 (0.58) | MAPTMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL16670011 | 0.65 | TAS1R3 (0.58) | MAPTMEN1KMT2AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573078-B1 | ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS | CHINESE PLA GENERAL HOSPITAL (CN) | 2016-11-02 | — | — | EP | disclosed |
| US-9439881-B2 | Acrylamide compounds and use thereof for inhibiting apoptosis | CHINESE PLA GENERAL HOSPITAL (CN) | 2016-09-13 | — | — | US | disclosed |
| US-9439881-B2 | Acrylamide compounds and use thereof for inhibiting apoptosis | CHINESE PLA GENERAL HOSPITAL (CN) | 2016-09-13 | — | — | US | disclosed |
| US-20160038445-A1 | ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS | CHINESE PLA GENERAL HOSPITAL (CN) | 2016-02-11 | — | — | US | disclosed |
| US-20160038445-A1 | ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS | CHINESE PLA GENERAL HOSPITAL (CN) | 2016-02-11 | — | — | US | disclosed |
| US-9199978-B2 | Acrylamide compounds and use thereof for inhibiting apoptosis | CHINESE PLA GENERAL HOSPITAL (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9199978-B2 | Acrylamide compounds and use thereof for inhibiting apoptosis | CHINESE PLA GENERAL HOSPITAL (CN) | 2015-12-01 | — | — | US | disclosed |
| US-20130158022-A1 | Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis | CHINESE PLA GENERAL HOSPITAL (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158022-A1 | Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis | CHINESE PLA GENERAL HOSPITAL (CN) | 2013-06-20 | — | — | US | disclosed |
| EP-2573078-A1 | ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS | Chinese PLA General Hospital (CN) | 2013-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038445-A1 | ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS | BAX, API5, BCL2 | MAPT 2397/4885MEN1 4214/4885KMT2A 4693/4885 |
| US-20130158022-A1 | Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis | BAX, API5, BCL2 | MAPT 2397/4885MEN1 4214/4885KMT2A 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.